Plus   Neg

Eaton Sees Q1, FY20 Earnings In Line With Estimates - Quick Facts

While reporting its financial results for the fourth quarter on Tuesday, power management company Eaton Corp plc (ETN) forecast adjusted earnings per share for the first quarter of 2020 to be between $1.16 and $1.26, a 4 percent decrease at the midpoint from the year-ago period.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $1.2 per share. Analysts' estimates typically exclude special items.

For fiscal 2020, Eaton projects adjusted earnings per share between $5.60 and $5.90, flat at the midpoint with 2019, excluding the 2019 vehicle warranty costs. The company forecast organic revenues to be between down 1 percent and up 1 percent versus 2019.

The Street expects earnings of $5.74 per share for the year on revenues of $20.28 billion.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Novacyt S.A. said it is seeing unprecedented demand for the novel coronavirus or COVID-19 diagnostic test kit developed by Primerdesign, the company's molecular diagnostics division based in the UK. As of March 27, Primerdesign has sold and received orders for more than 17.8 million pounds of its CE-Mark COVID-19 tests. Novacyt is currently selling its COVID-19 test to more than 80 countries. The U.S. Food and Drug Administration has issued an Emergency Use Authorization to allow anti-malaria drugs hydroxychloroquine sulfate and chloroquine phosphate donated to the Strategic National Stockpile as possible treatments for coronavirus (COVID-19) patients. This is the first EUA for a drug related to the COVID-19 response. Gilead Sciences Inc. said it is transitioning to "expanded access programs" from "compassionate use" programs for its experimental anti-coronavirus drug, remdesivir. The company noted that the expanded access will allow hospitals or physicians to apply for emergency use of remdesivir for multiple severely ill patients at one time, as they struggle to deal with the COVID-19 or coronavirus pandemic.
Follow RTT